Clinical trial
Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With…
NCT00096291 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00096291 |
|---|---|
| Title | Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With Large Breast Cancer |
| Official title | Neoadjuvant Chemotherapy in Palpable Breast Cancer: Evaluation of Physiologic, Radiologic, and Molecular Markers in Predicting Response |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Other |
| Interventions | Doxorubicin followed by Paclitaxel, Paclitaxel followed by Doxorubicin |
| Enrollment | 62 |
| Start date | Feb 1, 2000 |
| Primary completion | Mar 1, 2005 |
| First posted | Nov 9, 2004 |
| Last update posted | Apr 10, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: